Article

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains

2023-11-27

Abstract excerpt

Since the start of the SARS-CoV-2 pandemic, the search for antiviral therapies has been at the forefront of medical research. To date, the 3CLpro inhibitor nirmatrelvir (Paxlovid®) has shown the best results in clinical trials and the greatest robustness against variants. A second SARS-CoV-2 protease inhibitor, ensitrelvir (Xocova®), has been developed. Ensitrelvir, currently in Phase 3, was approved in Japan unde...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d7513eed-1f48-58ef-95b3-4abe61df524f
DOI: 10.1101/2023.11.22.568013

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strainsDOI 10.1101/2023.11.22.568013Read

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strainsSemantic proximity Read

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.Semantic proximity Read

A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity Read

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.Semantic proximity Read

Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populationsSemantic proximity Read

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvirSemantic proximity Read

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvirSemantic proximity Read

Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrierSemantic proximity Read

Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical geneticsSemantic proximity Read

Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system.Semantic proximity Read